The results of this phase II study in adults with CF (with or without concomitant use of CFTR modulators) showed that brensocatib was characterized by a rapid absorption, dose-dependent exposure, moderate rate of elimination, low-to-moderate inter-participant variability, and moderate exposure accumulation at steady state. Here, CFTR is linked to cystic fibrosis.